Dr. Olszanski on Patient Selection for Cemiplimab Treatment in CSCC

Anthony J. Olszanski, MD, RPh

Anthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase I Program, Fox Chase Cancer Center, discusses the treatment selection process for use of cemiplimab (Libtayo) in patients with cutaneous squamous cell carcinoma (CSCC).

For patients with CSCC who are referred to a medical oncologist, this means the surgeon has indicated that they are not candidates for surgical resection. In this case, a multidisciplinary tumor board review, including the surgeon, radiation oncologist, medical oncologist, and a dermatologist will unite to review the case to determine the best treatment plan, says Olszanski.

For those who are not candidates for surgery nor radiation therapy, Olszanski says that cemiplimab can play a vital role for treatment. This PD-L1 inhibitor has also been well tolerated, demonstrated high response rates, and can be easier to administer than chemotherapy.

<<< 2019 NCCN Annual Meeting
Printer Printing...